Evidence map›Paper›PMID 31919349›Full record

ReviewNature reviews. Disease primers2020

Opioid use disorder.

John Strang, Nora D Volkow, Louisa Degenhardt, Matthew Hickman, Kimberly Johnson, George F Koob, Brandon D L Marshall, Mark Tyndall, Sharon L Walsh

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Disease primers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 307 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
307citing papers in PubMed, 4 pooled it
55.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

307 citing papers in PubMed, 4 syntheses or guidelines pooled it, 582 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Article
  18. Article
  19. Toxidromes.Nature reviews. Disease primers · 2026
    Review
  20. Article

247 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 9 institutions in 4 countries.

John StrangNational Addiction Centre, Institute of Psychiatry Psychology & Neuroscience, King's College London, London, UK. john.strang@kcl.ac.uk.
Nora D VolkowNational Institute on Drug Abuse, National Institutes of Health, Rockville, MD, USA. nvolkow@nida.nih.gov.
Louisa DegenhardtNational Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales, Australia.
Matthew HickmanPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Kimberly JohnsonDepartment of Mental Health Law and Policy, College of Community and Behavioural Sciences, University of South Florida, Tampa, FL, USA.
George F KoobNational Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, MD, USA.
Brandon D L MarshallDepartment of Epidemiology, Brown University School of Public Health, Providence, RI, USA.
Mark TyndallSchool of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada.
Sharon L WalshDepartment of Behavioral Science, College of Medicine, University of Kentucky, Lexington, KT, USA.
Brown University · USKing's College London · GBNational Institute on Alcohol Abuse and Alcoholism · USNational Institute on Drug Abuse · USUniversity of Bristol · GBUniversity of British Columbia · CAUniversity of Kentucky · USUniversity of South Florida · USUNSW Sydney · AU

Funding

Neurobiology of Substance Abuse and AddictionZIAAA000550 · NIAAA · NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM · PI VOLKOW, NORA D. · 2009 to 2025
$115.1M
Project 4: Neonatal Abstinence Syndrome (NAS): Fetus to First YearsP20GM125507 · NIGMS · RHODE ISLAND HOSPITAL · PI Ju Nyeong Park · 2018 to 2026
$23.4M
Department of Health 12/136/105Department of Health RP-PG-0616-20008NIGMS NIH HHS P20 GM125507
6 · The paper itself

Abstract

Opioid use disorder (OUD) is a chronic relapsing disorder that, whilst initially driven by activation of brain reward neurocircuits, increasingly engages anti-reward neurocircuits that drive adverse emotional states and relapse. However, successful recovery is possible with appropriate treatment, although with a persisting propensity to relapse. The individual and public health burdens of OUD are immense; 26.8 million people were estimated to be living with OUD globally in 2016, with >100,000 opioid overdose deaths annually, including >47,000 in the USA in 2017. Well-conducted trials have demonstrated that long-term opioid agonist therapy with methadone and buprenorphine have great efficacy for OUD treatment and can save lives. New forms of the opioid receptor antagonist naltrexone are also being studied. Some frequently used approaches have less scientifically robust evidence but are nevertheless considered important, including community preventive strategies, harm reduction interventions to reduce adverse sequelae from ongoing use and mutual aid groups. Other commonly used approaches, such as detoxification alone, lack scientific evidence. Delivery of effective prevention and treatment responses is often complicated by coexisting comorbidities and inadequate support, as well as by conflicting public and political opinions. Science has a crucial role to play in informing public attitudes and developing fuller evidence to understand OUD and its associated harms, as well as in obtaining the evidence today that will improve the prevention and treatment interventions of tomorrow.

Indexed as

HumansNarcotic AntagonistsOpiate Substitution TreatmentOpioid-Related DisordersNarcotic Antagonists

Identifiers

PMID31919349
OpenAlexW3000475066

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.